These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 15118538

  • 1. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis.
    Bajzar L, Jain N, Wang P, Walker JB.
    Crit Care Med; 2004 May; 32(5 Suppl):S320-4. PubMed ID: 15118538
    [Abstract] [Full Text] [Related]

  • 2. Insights into thrombin activatable fibrinolysis inhibitor function and regulation.
    Foley JH, Kim PY, Mutch NJ, Gils A.
    J Thromb Haemost; 2013 Jun; 11 Suppl 1():306-15. PubMed ID: 23809134
    [Abstract] [Full Text] [Related]

  • 3. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
    Miljić P, Heylen E, Willemse J, Djordjević V, Radojković D, Colović M, Elezović I, Hendriks D.
    Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():74-8. PubMed ID: 20229688
    [Abstract] [Full Text] [Related]

  • 4. Thrombin-activatable fibrinolysis inhibitor.
    Marx PF.
    Curr Med Chem; 2004 Sep; 11(17):2335-48. PubMed ID: 15379716
    [Abstract] [Full Text] [Related]

  • 5. Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides.
    Plug T, Marquart JA, Marx PF, Meijers JC.
    J Thromb Haemost; 2015 Nov; 13(11):2093-101. PubMed ID: 26341360
    [Abstract] [Full Text] [Related]

  • 6. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a.
    Semeraro F, Ammollo CT, Gils A, Declerck PJ, Colucci M.
    J Thromb Haemost; 2013 Dec; 11(12):2137-47. PubMed ID: 24134522
    [Abstract] [Full Text] [Related]

  • 7. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
    Zhou X, Weeks SD, Ameloot P, Callewaert N, Strelkov SV, Declerck PJ.
    J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497
    [Abstract] [Full Text] [Related]

  • 8. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
    Bazzi ZA, Lanoue D, El-Youssef M, Romagnuolo R, Tubman J, Cavallo-Medved D, Porter LA, Boffa MB.
    BMC Cancer; 2016 May 24; 16():328. PubMed ID: 27221823
    [Abstract] [Full Text] [Related]

  • 9. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis.
    Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L.
    Thromb Haemost; 1997 Jul 24; 78(1):386-91. PubMed ID: 9198184
    [Abstract] [Full Text] [Related]

  • 10. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
    Bouma BN, Meijers JC.
    J Thromb Haemost; 2003 Jul 24; 1(7):1566-74. PubMed ID: 12871292
    [Abstract] [Full Text] [Related]

  • 11. Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment.
    Bazzi ZA, Balun J, Cavallo-Medved D, Porter LA, Boffa MB.
    Clin Exp Metastasis; 2017 Feb 24; 34(2):155-169. PubMed ID: 28124276
    [Abstract] [Full Text] [Related]

  • 12. [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].
    Stasko J, Hudecek J, Kubisz P.
    Vnitr Lek; 2004 Jan 24; 50(1):36-44. PubMed ID: 15015228
    [Abstract] [Full Text] [Related]

  • 13. Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction.
    Toh CH.
    Blood Coagul Fibrinolysis; 2003 Jun 24; 14 Suppl 1():S69-71. PubMed ID: 14567541
    [Abstract] [Full Text] [Related]

  • 14. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis.
    Bouma BN, Mosnier LO.
    Pathophysiol Haemost Thromb; 2003 Jun 24; 33(5-6):375-81. PubMed ID: 15692247
    [Abstract] [Full Text] [Related]

  • 15. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP, Blombäck M.
    Thromb Res; 2002 Apr 01; 106(1):59-62. PubMed ID: 12165290
    [Abstract] [Full Text] [Related]

  • 16. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation.
    Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, Pearl RG, Leung LL.
    J Biol Chem; 2003 Dec 19; 278(51):51059-67. PubMed ID: 14525995
    [Abstract] [Full Text] [Related]

  • 17. Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.
    Sillen M, Declerck PJ.
    Int J Mol Sci; 2021 Apr 01; 22(7):. PubMed ID: 33916027
    [Abstract] [Full Text] [Related]

  • 18. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.
    Foley JH, Kim P, Nesheim ME.
    J Biol Chem; 2008 Apr 04; 283(14):8863-7. PubMed ID: 18252711
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.